iRadimed (NASDAQ:IRMD) Updates Q1 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its first quarter 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.440-0.480 for the period, compared to the consensus estimate of 0.440. The company issued revenue guidance of $21.0 million-$22.0 million, compared to the consensus revenue estimate of $20.8 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

Analyst Ratings Changes

A number of research firms recently weighed in on IRMD. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research raised shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital reissued a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Roth Mkm set a $90.00 price objective on iRadimed in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, iRadimed presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

iRadimed Stock Performance

Shares of NASDAQ:IRMD traded up $8.98 on Tuesday, hitting $104.95. 26,731 shares of the company’s stock were exchanged, compared to its average volume of 74,355. iRadimed has a 1-year low of $47.48 and a 1-year high of $107.90. The company has a market capitalization of $1.33 billion, a PE ratio of 63.60 and a beta of 1.11. The firm’s 50-day moving average is $97.82 and its 200 day moving average is $83.09.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $22.69 million for the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, analysts anticipate that iRadimed will post 1.66 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is presently 41.21%.

Insider Buying and Selling

In other iRadimed news, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. The trade was a 67.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the sale, the chief executive officer directly owned 2,262,500 shares in the company, valued at approximately $227,720,625. This represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 55,000 shares of company stock worth $5,287,900. Company insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several large investors have recently bought and sold shares of IRMD. Algert Global LLC boosted its position in shares of iRadimed by 87.5% in the third quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock valued at $3,615,000 after acquiring an additional 23,710 shares during the period. UBS Group AG lifted its holdings in shares of iRadimed by 389.9% during the third quarter. UBS Group AG now owns 25,433 shares of the medical equipment provider’s stock valued at $1,810,000 after acquiring an additional 20,242 shares during the period. Punch & Associates Investment Management Inc. bought a new stake in shares of iRadimed in the 3rd quarter worth about $1,210,000. Two Sigma Investments LP boosted its position in iRadimed by 33.4% in the third quarter. Two Sigma Investments LP now owns 53,647 shares of the medical equipment provider’s stock valued at $3,818,000 after buying an additional 13,417 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after buying an additional 11,139 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.